Cargando…

Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review

BACKGROUND AND OBJECTIVE: First-line treatment options for patients with advanced non-small cell lung cancer (aNSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have rapidly evolved from chemotherapy, to the first in class ALK-targeted tyrosine kinase inhibitor (TKI) c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chazan, Grace, Solomon, Benjamin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989801/ https://www.ncbi.nlm.nih.gov/pubmed/36895924 http://dx.doi.org/10.21037/tlcr-22-656

Ejemplares similares

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi, Shipra, et al.
Publicado: (2015)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns, Mark W, et al.
Publicado: (2015)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
por: Sivignon, Marine, et al.
Publicado: (2020)

Radiographic Features of Metastatic Brain Tumors from ALK-rearranged Non-small Cell Lung Cancer: Implications for Optimal Treatment Modalities
por: Chu, Li, et al.
Publicado: (2019)

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2018)

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
por: Desai, Aakash, et al.
Publicado: (2023)

A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
por: Hernandez, Susana, et al.
Publicado: (2023)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise, Amy M, et al.
Publicado: (2014)

A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer
por: Wang, Wan-Qing, et al.
Publicado: (2023)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015)

Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion
por: Lei, Yanna, et al.
Publicado: (2023)

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Cruz, Barbara D., et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors
por: Wu, Yanyu, et al.
Publicado: (2022)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
por: Ma, Hao-chuan, et al.
Publicado: (2021)

Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Lin, Kehai, et al.
Publicado: (2022)

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden
por: Naik, Jaesh, et al.
Publicado: (2023)

First-line management of metastatic non-small cell lung cancer: An Indian perspective
por: Ghadyalpatil, Nikhil Suresh, et al.
Publicado: (2019)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
por: Ali, Robert, et al.
Publicado: (2019)

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
por: Liu, Geoffrey, et al.
Publicado: (2023)

Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
por: Singh, Abhay, et al.
Publicado: (2020)

Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis
por: Wen, Yaokai, et al.
Publicado: (2022)

First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view
por: Thatcher, Nicholas
Publicado: (2008)

Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer
por: Stares, Mark, et al.
Publicado: (2021)

Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
por: Engel-Nitz, Nicole M., et al.
Publicado: (2020)

Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
por: Poh, Mau Ern, et al.
Publicado: (2023)

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort
por: Zou, Zihua, et al.
Publicado: (2022)

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
por: Costa, Rubens Barros, et al.
Publicado: (2018)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

104P Exploring the real-world impact of COVID-19 on first line (1L) treatment and management of EGFR-wild type (EGFR-WT) and ALK-wild type (ALK-WT) metastatic non-small cell lung cancer (mNSCLC) across Europe
por: Bailey, H., et al.
Publicado: (2021)

The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
por: Zheng, Bei, et al.
Publicado: (2023)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
por: Pai‐Scherf, Lee, et al.
Publicado: (2017)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e07prfatjpnu4u65oosh11prc9